Renal disorders in rheumatologic diseases: the spectrum is changing (Part 1: connective tissue diseases).
Lupus nephritis
Malignant hypertension
Myoglobinuria
Polymyositis
Scleroderma
Sjögren syndrome
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
27
04
2020
accepted:
03
06
2020
pubmed:
13
6
2020
medline:
16
9
2021
entrez:
13
6
2020
Statut:
ppublish
Résumé
The kidney is frequently involved by autoimmune rheumatic diseases. The renal manifestations may be variable, ranging from asymptomatic proteinuria and microscopic haematuria to nephrotic syndrome and rapidly progressive glomerulonephritis or vasculitis. In a number of cases the kidney involvement is related to the treatment of the original disease and may represent a major cause of morbidity and mortality. Thus, it is important for nephrologists and rheumatologists to remember that dysfunction of the kidney may be part of the primary systemic disorder or consequence of its pharmacotherapy. In the first part of this review we will analyse the kidney involvement in four autoimmune connective tissue diseases: systemic lupus erythematosus, Sjögren syndrome, polymyositis/dermatomyositis, and systemic sclerosis. Renal disease is common in lupus and is a main cause of morbidity and mortality. About 10% of patients with Sjögren syndrome may present interstitial nephritis or, more rarely, glomerulonephritis. Myoglobinuria and acute kidney injury is a frequent complication of polymyositis. Renal disease is one of the most serious complications of systemic sclerosis and may present with a dramatic renal crisis, characterized by malignant hypertension, oligo-anuria, and microangiopathic thrombocytopenic anaemia.
Identifiants
pubmed: 32529559
doi: 10.1007/s40620-020-00772-7
pii: 10.1007/s40620-020-00772-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1069-1080Informations de copyright
© 2020. Italian Society of Nephrology.
Références
Bonanni A, Vaglio A, Bruschi M, Sinico RA, Cavagna L, Moroni G et al (2015) Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference. Autoimmun rev 14(8):692–702
pubmed: 25888464
doi: 10.1016/j.autrev.2015.04.004
pmcid: 25888464
Bruschi M, Sinico RA, Moroni G, Pratesi F, Migliorini P, Galetti M et al (2014) Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. J Am Soc Nephrol 25(11):2483–2498
pubmed: 24790181
doi: 10.1681/ASN.2013090987
pmcid: 24790181
Kinloch AJ, Chang A, Ko K, Dunand CJH, Henderson S, Maienschein-Cline M et al (2014) Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis arthritis. Rheumatol 66(12):3359–3370
Bruschi M, Galetti M, Sinico RA, Moroni G, Bonanni A, Radice A et al (2015) Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J Am Soc Nephrol 26(8):1905–1924
pubmed: 25398787
doi: 10.1681/ASN.2014050493
pmcid: 25398787
Davidson A (2016) (2016) What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol 12:143–153
pubmed: 26581344
doi: 10.1038/nrrheum.2015.159
pmcid: 26581344
Fu J, Lee K, Chuang PY, Liu Z, He JC (2015) Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol 308(4):F287–F297
pubmed: 25411387
doi: 10.1152/ajprenal.00533.2014
pmcid: 25411387
Maria NI, Davidson A (2020) Protecting the kidney in systemic lupus erythematosus:from diagnosis to therapy. Nat Rev Rheumatol 12:67. https://doi.org/10.1038/s41584-020-0401-9
doi: 10.1038/s41584-020-0401-9
Crow MK (2014) Type I interferon in the pathogenesis of lupus. J Immunol 192:5459–5468
pubmed: 24907379
doi: 10.4049/jimmunol.1002795
pmcid: 24907379
Bassi NA, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A et al (2010) IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 69:1704–1710
pubmed: 20439287
doi: 10.1136/ard.2009.117804
pmcid: 20439287
de Oliveira T, Souza DG, Teixeira MM, Amaral FA (2019) Tissue dependent role of PTX3 during ischemia-reperfusion injury. Front Immunol 10:1461
pubmed: 31354697
doi: 10.3389/fimmu.2019.01461
pmcid: 31354697
Bassi N, Del Prete D, Ghirardello A, Gatto M, Ceol M, Zen M et al (2015) PTX3, anti-PTX3, and anti-C1q autoantibodies in lupus glomerulonephritis. Clin Rev Allergy Immunol 49:217–226
pubmed: 25805362
doi: 10.1007/s12016-015-8476-9
pmcid: 25805362
Gatto M, Radu C, Luisetto R, Ghirardello A, Bonsembiante F, Trez D et al (2020) Immunization with pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: insights from renal ultrastructural findings. J Autoimmun. https://doi.org/10.1016/j.jaut.2020.102443
doi: 10.1016/j.jaut.2020.102443
pubmed: 32527675
pmcid: 32527675
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15(2):241–250
pubmed: 14747370
doi: 10.1097/01.ASN.0000108969.21691.5D
pmcid: 14747370
Sciascia S, Radin M, Cecchi I, Fenoglio R, De Marchi A, Besso L, Baldovino S et al (2020) Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. J Nephrol 1:8. https://doi.org/10.1007/s40620-019-00698-9
doi: 10.1007/s40620-019-00698-9
Ding X, Chen C, Zhang J, Lu G (2020) Antiphospholipid antibodies in patients with proliferative and membranous lupus nephritis. Clin Rheumatol 39(5):1531–1535
pubmed: 31933032
doi: 10.1007/s10067-019-04917-3
pmcid: 31933032
Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I et al (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713–723
pubmed: 32220834
doi: 10.1136/annrheumdis-2020-216924
pmcid: 32220834
Wakasugi D, Gono T, Kawaguchi Y, Hara M, Koseki Y, Katsumata Y et al (2012) Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol 39(1):79–85
pubmed: 22089455
doi: 10.3899/jrheum.110532
pmcid: 22089455
Christopher-Stine L, Siedner M, Lin J, Haas M, Parekh H, Petri M, Fine DM (2007) Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 34(2):332–335
pubmed: 17183619
pmcid: 17183619
Almaani S, Meara A, Rovin BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12(5):825–835
doi: 10.2215/CJN.05780616
Moroni G, Depetri F, Ponticelli C (2016) Lupus nephritis: when and how often to biopsy and what does it mean? J Autoimmun 74:27–40
pubmed: 27349351
doi: 10.1016/j.jaut.2016.06.006
pmcid: 27349351
Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C (2013) Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. Lupus 22(8):80–88
doi: 10.1177/0961203313492576
Parodis I, Tamirou F, Houssiau FA (2020) Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med 18(1):389. https://doi.org/10.1136/lupus-2020-000389
doi: 10.1136/lupus-2020-000389
Falasinnu T, O’Shaughnessy M, Troxell ML, Charu V, Weisman H, Simard JF (2019) A review of non-immune mediated kidney disease in sytemic lupus erythematosus: a hypothetical model of putative risk factors. Semin Arthritis Rheum 49(19):30702–30704. https://doi.org/10.1016/j.semarthrit.2019.10.006
doi: 10.1016/j.semarthrit.2019.10.006
Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D (2014) Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol 10(5):279–289
pubmed: 24642799
doi: 10.1038/nrneph.2014.38
pmcid: 24642799
Hajji M, Jebali H, Mrad A, Blel Y, Brahmi N, Kheder R et al (2018) Nephrotoxicity of ciprofloxacin: five cases and a review of the literature. Drug Saf Case Rep 18(1):17
doi: 10.1007/s40800-018-0073-4
Milburn J, Jones R, Levy JB (2017) Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant 32(3):434–439
pubmed: 27190354
pmcid: 27190354
Bakhriansyah M, Souverein PC, van den Hoogen MWF, de Boer A, Klungel OH (2019) Risk of nephrotic syndrome for non-steroidal anti-inflammatory drug users. Clin J Am Soc Nephrol 14(9):1355–1362
pubmed: 31416888
doi: 10.2215/CJN.14331218
pmcid: 31416888
Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK (2019) (2019) All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol 71(3):403–410
pubmed: 30225916
doi: 10.1002/art.40729
pmcid: 30225916
Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L et al (2018) Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 77(9):1318–1325
pubmed: 29730634
doi: 10.1136/annrheumdis-2017-212732
pmcid: 29730634
Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido R, Danieli MG et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46(8):2121–2131
pubmed: 12209517
doi: 10.1002/art.10461
pmcid: 12209517
Ponticelli C, Glassock RJ, Moroni G (2010) Induction and maintenance therapy in proliferative lupus nephritis. J Nephrol 23(1):9–16
pubmed: 20091481
pmcid: 20091481
Deng J, Huo D, Wu Q, Yang Z, Liao Y (2012) A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med 227(4):281–288
pubmed: 22820853
doi: 10.1620/tjem.227.281
pmcid: 22820853
Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del N et al (2014) Rituximab vs. mycophenolate and vs. cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford) 53(9):1570–1577
doi: 10.1093/rheumatology/ket462
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64:1215–1226
pubmed: 22231479
doi: 10.1002/art.34359
pmcid: 22231479
Almaani S, Rovin BH (2019) B-cell therapy in lupus nephritis: an overview. Nephrol Dial Transplant 34(1):22–29
pubmed: 30165690
doi: 10.1093/ndt/gfy267
pmcid: 30165690
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et al (2011) ALMS group mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365(20):1886–1895
pubmed: 22087680
doi: 10.1056/NEJMoa1014460
Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S et al (2006) A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over 4 years. Clin J Am Soc Nephrol 1(5):925–932
pubmed: 17699309
doi: 10.2215/CJN.02271205
Sheikholeslami M, Hajialilo M, Rasi Hashemi SS, Malek Mahdavi A, Gojazadeh M, Khabbazi A (2018) Low dose cyclosporine a in the treatment of resistant proliferative lupus nephritis. Mod Rheumatol 28(3):523–529
pubmed: 28753077
doi: 10.1080/14397595.2017.1352479
Ayoub I, Rovin BH (2017) Calcineurin inhibitors in the treatment of lupus nephritis: a hare versus turtle story? J Am Soc Nephrol 28(12):3435–3437
pubmed: 28982696
doi: 10.1681/ASN.2017080830
pmcid: 5698081
Rovin BH, Solomons N, Pendergraft WF, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB (2019) A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95(1):219–231
pubmed: 30420324
doi: 10.1016/j.kint.2018.08.025
Binda V, Trezzi B, Del Papa N, Beretta L, Frontini G, Porata G et al (2020 Jan 30) 2020) Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient. J Nephrol. https://doi.org/10.1007/s40620-020-00706-3
doi: 10.1007/s40620-020-00706-3
pubmed: 32462476
Zhang H, Liu Z, Zhou M, Liu Z, Chen J, Xing C et al (2017) Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 28(12):3671–3678
pubmed: 28760751
doi: 10.1681/ASN.2017030263
pmcid: 5698076
Ponticelli C, Moroni G (2017) Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 16(3):411–419
pubmed: 27927040
doi: 10.1080/14740338.2017.1269168
Moroni G, Longhi S, Giglio E, Messa P, Ponticelli C (2013) What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol 31(4 Suppl 78):S75–81
pubmed: 24129143
Malvar A, Alberton V, Lococo B, Ferrari M, Delgado P, Nagaraja HN, Rovin BH (2020) Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int 97(1):156–162
pubmed: 31685314
doi: 10.1016/j.kint.2019.07.018
pmcid: 31685314
Francois H, Mariette X (2016) Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol 12(2):82–93
pubmed: 26568188
doi: 10.1038/nrneph.2015.174
pmcid: 26568188
Jasiek M, Karras A, Le Guern V, Krastinova E, Mesbah R, Faguer S et al (2017) A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome. Rheumatology (Oxford) 56(3):362–370
Evans RD, Laing CM, Ciurtin C, Walsh SB (2016) Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment. BMC Musculoskelet Disord 5(17):2. https://doi.org/10.1186/s12891-015-0858-x
doi: 10.1186/s12891-015-0858-x
Sandhya P, Danda D, Rajaratnam S, Thomas N (2014) Sjögren’s, renal tubular acidosis and osteomalacia–An Asian Indian Series. Open Rheumatol J 8:103–109
pubmed: 25584094
doi: 10.2174/1874312901408010103
pmcid: 25584094
Krieger NS, Frick KK, Bushinsky DA (2004) Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens 13(4):423–436
pubmed: 15199293
doi: 10.1097/01.mnh.0000133975.32559.6b
pmcid: 15199293
Vallés PG, Batlle D (2018) Hypokalemic Distal renal tubular acidosis. Hypokalemic distal renal tubular acidosis. Adv Chronic Kidney Dis 25(4):303–320
pubmed: 30139458
doi: 10.1053/j.ackd.2018.05.003
pmcid: 30139458
Haque SK, Ariceta G, Battle D (2012) Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant 27(12):4273–4287
pubmed: 23235953
doi: 10.1093/ndt/gfs493
pmcid: 23235953
Rodriguez Soriano J (2002) Renal tubular acidosis: the clinical entity. J Am Soc Nephrol 13:2160–2170
pubmed: 12138150
doi: 10.1097/01.ASN.0000023430.92674.E5
pmcid: 12138150
Yang YS, Peng CH, Sia SK, Huang CN (2007) Acquired hypophosphatemia osteomalacia associated with Fanconi’s syndrome in Sjögren’s syndrome. Rheumatol Int 27(6):593–597
pubmed: 17094001
doi: 10.1007/s00296-006-0257-6
pmcid: 17094001
Kobayashi T, Muto S, Nemoto J, Miyata Y, Ishiharajima S, Hironaka M et al (2006) Fanconi’s syndrome and distal (type 1) renal tubular acidosis in a patient with primary Sjögren’s syndrome with monoclonal gammopathy of undetermined significance. Clin Nephrol 65(6):427–432
pubmed: 16792139
doi: 10.5414/CNP65427
Bredberg A, Henriksson G, Larsson A et al (2003) A role of the macrophage in Sjögen’s syndrome? Scand J Rheumatol 32:255
pubmed: 14626635
doi: 10.1080/03009740310003785
Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV, Hogan MC (2009) Renal involvement in primary Sjögren’s syndrome: a clinicopathologic study. Clin J Am Soc Nephrol 4(9):1423–1431
pubmed: 19679669
doi: 10.2215/CJN.00980209
pmcid: 2736689
Bossini N, Savoldi S, Franceschini F, Mombelloni S, Baronio M et al (2001) Clinical and morphological features of kidney involvement in primary Sjögren’s syndrome. Nephrol Dial Transplant 16(12):2328–2333
pubmed: 11733624
doi: 10.1093/ndt/16.12.2328
Kidder D, Rutherford E, Kipgen D et al (2015) Kidney biopsy findings in primary Sjögren syndrome. Nephrol Dial Transplant 30(8):1363–1369
pubmed: 25817222
doi: 10.1093/ndt/gfv042
pmcid: 25817222
Yang HX, Wang J, Wen YB, Fei YY, Jiang MD, Zhou MY (2018) Renal involvement in primary Sjögren’s syndrome: a retrospective study of 103 biopsy-proven cases from a single center in China. Int J Rheum Dis 21(1):223–229
pubmed: 28941123
doi: 10.1111/1756-185X.13182
pmcid: 28941123
François H, Mariette X (2016) (2016) Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol 12(2):82–93
pubmed: 26568188
doi: 10.1038/nrneph.2015.174
pmcid: 26568188
Dabadghao S, Aggarwal A, Arora P, Pandey R, Misra R (1995) Glomerulonephritis leading to end stage renal disease in a patient with primary Sjogren syndrome. Clin Exp Rheumatol 13:509–511
pubmed: 7586787
pmcid: 7586787
Cortez MS, Sturgill BC, Bolton WK (1995) Membranoproliferative glomerulonephritis with primary Sjogren’s syndrome. Am J Kidney Dis 25:632–636
pubmed: 7702063
doi: 10.1016/0272-6386(95)90136-1
pmcid: 7702063
Pasoto SG, de Adriano V, Bonfa E (2019) Sjögren’s syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol 11:33–45
pubmed: 30774485
doi: 10.2147/OARRR.S167783
pmcid: 30774485
Imgenberg-Kreuz J, Almlöf JC, Leonard D, Sjöwall C, Syvänen AC, Rönnblom L et al (2019) Shared and unique patterns of dna methylation in systemic lupus erythematosus and primary Sjögren’s syndrome. Front Immunol 10:1686
pubmed: 31428085
doi: 10.3389/fimmu.2019.01686
pmcid: 31428085
Anand A, Krishna GG, Sibley RK, Kambham N (2015) Sjögren syndrome and cryoglobulinemic glomerulonephritis. Am J Kidney Dis 66(3):532–535
pubmed: 25661680
doi: 10.1053/j.ajkd.2014.11.032
pmcid: 25661680
Goules AV, Tatouli IP, Moutsopoulos HM, Tzioufas AG (2013) Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome. Arthr Rheum 65(11):2945–2953
doi: 10.1002/art.38100
Kidder D, Rutherford E, Kipgen D, Fleming S, Geddes C, Stewart GA (2015) Kidney biopsy findings in primary Sjögren syndrome. Nephrol Dial Transplant 30(8):1363–1369
pubmed: 25817222
doi: 10.1093/ndt/gfv042
pmcid: 25817222
Evans RDR, Laing CM, Ciurtin C, Walsh SB (2016) Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment. BMC Musculoskelet Disord 17:2
pubmed: 26728714
doi: 10.1186/s12891-015-0858-x
pmcid: 26728714
Jain A, Srinivas BH, Emmanuel D, Jain VK, Parameshwaran FS, Negi VS (2018) Renal involvement in primary Sjogren’s syndrome: a prospective cohort study. Rheumatol Int 38(12):2251–2262
pubmed: 30155666
doi: 10.1007/s00296-018-4118-x
pmcid: 30155666
Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, Dörner T et al (2020) EULAR-Sjögren syndrome task force group. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 79(1):3–18
pubmed: 31672775
doi: 10.1136/annrheumdis-2019-216114
pmcid: 31672775
Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 373:393–394
pubmed: 26200989
doi: 10.1056/NEJMc1506827
pmcid: 26200989
Christopher-Stine L, Plotz PH (2004) Myositis: an update on pathogenesis. Curr Opin Rheumatol 16:700–706
pubmed: 15577607
doi: 10.1097/01.bor.0000141925.21941.d8
pmcid: 15577607
Yen TH, Lai PC, Chen CC, Hsueh S, Huang JY (2005) Renal involvement in patients with polymyositis and dermatomyositis. Int J Clin Pract 59(2):188–193
pubmed: 15854195
doi: 10.1111/j.1742-1241.2004.00248.x
pmcid: 15854195
Couvrat-Desvergnes G, Masseau A, Benveniste O, Bruel A, Hervier B, Mussini JM et al (2014) The spectrum of renal involvement in patients with inflammatory myopathies. Medicine (Baltimore) 93(1):33–41
doi: 10.1097/MD.0000000000000015
Kim HW, Choi JR, Jang SJ, Chang YS, Bang BK, Park CW (2005) Recurrent rhabdomyolysis and myoglobinuric acute renal failure in a patient with polymyositis. Nephrol Dial Transplant 20(10):2255–2258
pubmed: 15985512
doi: 10.1093/ndt/gfh950
pmcid: 15985512
Cucchiari D, Angelini C (2017) Renal involvement in Idiopathic inflammatory Myopathies. Clin Rev Allergy Immunol 52(1):99–107
pubmed: 26590948
doi: 10.1007/s12016-015-8524-5
pmcid: 26590948
Thakur V, DeSalvo J, McGrath H, Weed S, Garcia C (1996) Case report: Polymyositis-induced myoglobinuric acute renal failure. Am J Med Sci 312:85–87
pubmed: 8701971
pmcid: 8701971
Lewington AJ, D’Souza R, Carr S, O’Reilly K, Warwick GL (1996) Polymyositis: a cause of acute renal failure. Nephrol Dial Transplant 11:699–701
pubmed: 8671863
doi: 10.1093/oxfordjournals.ndt.a027364
pmcid: 8671863
Zager RA (1996) Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 49:314–326
pubmed: 8821813
doi: 10.1038/ki.1996.48
pmcid: 8821813
Marisiddappa L, Desai AM, Kedlaya PG, Sathish R (2018) Recurrent Episodic myoglobinuric acute kidney injury as presenting manifestation of idiopathic polymyositis. Saudi J Kid Dis Transpl 29(1):210–213
doi: 10.4103/1319-2442.225181
Bosch X, Poch E, Grau JM (2009) Rhabdomyolysis and acute kidney injury. N Engl J Med 2(1):62–72
doi: 10.1056/NEJMra0801327
Mantoo MR, Tripathy SK, Phulware RH, Bagri NK, Hari P, Barwad A (2019) Juvenile dermatomyositis with IgA nephropathy: case-based review. Rheumatol Int 39(3):577–581
pubmed: 30552457
doi: 10.1007/s00296-018-4229-4
pmcid: 30552457
Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of systemic sclerosis. Front Immunol 6:272
pubmed: 26106387
doi: 10.3389/fimmu.2015.00272
pmcid: 26106387
Santaniello A, Salazar G, Lenna S, Antonioli R, Colombo G, Beretta L et al (2006) HLA-B35 upregulates the production of endothelin-1 in HLA-transfected cells: a possible pathogenetic role in pulmonary hypertension. Tissue Antigens 68(3):239–244
pubmed: 16948645
doi: 10.1111/j.1399-0039.2006.00657.x
pmcid: 16948645
Lenna S, Townsend DM, Tan FK, Kapanadze B, Markiewicz M, Trojanowska M et al (2010) HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells. J Immunol 84(9):4654–4661
doi: 10.4049/jimmunol.0903188
Martin JE, Assassi S, Diaz-Gallo LM, Broen JC, Simeon CP, Castellvi I et al (2013) A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet 22(19):4021–4029
pubmed: 23740937
doi: 10.1093/hmg/ddt248
pmcid: 23740937
Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, Denton CP (2013) Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 106(9):839–848
pubmed: 23696678
doi: 10.1093/qjmed/hct111
pmcid: 23696678
Takagi K, Kawaguchi Y, Hara M, Sugiura T, Harigai M, Kamatani N (2003) Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 134(3):538–544
pubmed: 14632763
doi: 10.1111/j.1365-2249.2003.02320.x
pmcid: 14632763
Shiwen X, Leask A, Abraham DJ, Fonseca C (2009) Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma. Eur J Clin Invest 39(Suppl 2):19–26
pubmed: 19335743
doi: 10.1111/j.1365-2362.2009.02117.x
pmcid: 19335743
Postlethwaite AE, Chiang TM (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19(6):574–599
pubmed: 17917538
doi: 10.1097/BOR.0b013e3282eeb3a4
pmcid: 17917538
Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166(3):255–263
pubmed: 1517881
doi: 10.1002/path.1711660307
pmcid: 1517881
Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100(8):485–494
pubmed: 17601770
doi: 10.1093/qjmed/hcm052
pmcid: 17601770
Helfrich DJ, Banner B, Steen VD, Medsger TA (1989) Normotensive renal failure in systemic sclerosis. Arthritis Rheum 32(9):1128–1134
pubmed: 2775321
doi: 10.1002/anr.1780320911
pmcid: 2775321
Yamashita H, Kamei R, Kaneko H (2019) Classifications of scleroderma renal crisis and reconsideration of its pathophysiology. Rheumatology (Oxford) 58(12):2099–2106
doi: 10.1093/rheumatology/kez435
Black CM, Denton CP (2005) The patient with scleroderma-systemic sclerosis. In: Davison AM, Cameron JS, Grunfeld JP, Ponticelli C, Ritz E, Winearls CG, van Ypersele C (eds) Oxford Textbook of Clinical Nephrology, 3rd edn. Oxford University Press, Oxford, pp 843–854
Batal I, Domsic RT, Medsger TA, Bastacky S (2010) Scleroderma crisis: a pathology perspective. Int J Rheumatol 5:4–37. https://doi.org/10.1155/2010/543704
doi: 10.1155/2010/543704
Ichikawa K, Konta T, Sato H, Ueda Y, Yokoyama H (2017) The clinical and pathological characteristics of nephropathies in connective tissue diseases in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 21(6):1024–1029
pubmed: 28255922
doi: 10.1007/s10157-017-1398-5
pmcid: 28255922
Traub XM (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of 25 year experience with 68 cases. Medicine 62:335–352
pubmed: 6355755
doi: 10.1097/00005792-198311000-00001
pmcid: 6355755
Bose N, Chiesa-Vottero A, Chatterjee S (2015) Scleroderma renal crisis. Semin Arthritis Rheum 44(6):687–694
pubmed: 25613774
doi: 10.1016/j.semarthrit.2014.12.001
pmcid: 25613774
Turk M, Pope JE (2016) The frequency of scleroderma renal crisis over time: a metaanalysis. J Rheumatol 43(7):1350–1355
pubmed: 27134252
doi: 10.3899/jrheum.151353
pmcid: 27134252
Steen JP, Shapiro AP, Medsger TA (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113:352–357
pubmed: 2382917
doi: 10.7326/0003-4819-113-5-352
pmcid: 2382917
Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M et al (2003) Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 33(5–6):216–220
pubmed: 12752889
doi: 10.1046/j.1445-5994.2003.00358.x
pmcid: 12752889
Steen VD, Medsger TA (2000) Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133:600–603
pubmed: 11033587
doi: 10.7326/0003-4819-133-8-200010170-00010
pmcid: 11033587
Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100(8):485–494
pubmed: 17601770
doi: 10.1093/qjmed/hcm052
pmcid: 17601770
Cozzi F, Marson P, Cardarelli S, Favaro M, Tison T, Tonello M et al (2012) Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant 27(12):4398–4403
pubmed: 22859795
doi: 10.1093/ndt/gfs317
pmcid: 22859795
Lavergne A, Pladys A, Couchoud C, Lassalle M, Vigneau C (2020) Systemic sclerosis and end-stage renal disease: study of patient characteristics, follow-up and outcomes in France. J Nephrol. 24:12. https://doi.org/10.1007/s40620-020-00746-9
doi: 10.1007/s40620-020-00746-9
Caplin NJ, Dikman S, Winston J, Spiera H, Uribarri J (1999) Recurrence of scleroderma in a renal allograft from an identical twin sister. Am J Kidney Dis 33(4):7
doi: 10.1016/S0272-6386(99)70248-9
Saxena N, Djamali A, Astor BC, Mohamed M, Mandelbrot D, Parajuli S (2017) A single center kidney transplant experience among ten Caucasian females with end-stage renal disease due to scleroderma. Clin Nephrol 88(1):40–44
pubmed: 28406085
doi: 10.5414/CN109107
pmcid: 28406085
Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685–1699
pubmed: 28413064
doi: 10.1016/S0140-6736(17)30933-9
pmcid: 28413064
Brokmann JC, Rossaint R, Müller M, Fitzner C, Villa L, Beckers SK, Bergrath S (2017) Blood pressure management and guideline adherence in hypertensive emergencies and urgencies: a comparison between telemedically supported and conventional out-of-hospital care. J Clin Hypertens (Greenwich) 19(7):704–712
doi: 10.1111/jch.13026
Shah M, Patil S, Patel B, Arora S, Patel N, Garg L (2017) Trends in hospitalization for hypertensive emergency, and relationship of end-organ damage with in-hospital mortality. Am J Hypertens 30(7):700–706
pubmed: 28430850
doi: 10.1093/ajh/hpx048
pmcid: 28430850
van der Merwe W, van der Merwe V (2013) Malignant hypertension: a preventable emergency. N Z Med 126(1380):39–45
Zanatta E, Polito P, Favaro M, Larosa M, Marson P, Cozzi F, Doria A (2018) Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev 17(9):882–889
pubmed: 30005860
doi: 10.1016/j.autrev.2018.03.012
pmcid: 30005860
Montanelli G, Beretta L, Santaniello A, Scorza R (2013) Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 31(2 Suppl 76):135–139
pubmed: 23295023
pmcid: 23295023
Nagaraja V (2019) Management of scleroderma renal crisis. Curr Opin Rheumatol 31(3):223–230
pubmed: 30870219
doi: 10.1097/BOR.0000000000000604
pmcid: 30870219
Kfoury Baz EM, Mahfouz RA, Masri AF, Jamaleddine GW (2001) Thrombotic thrombocytopenic purpura in a case of scleroderma renal crisis treated with twice-daily therapeutic plasma exchange. Ren Fail 23(5):737–742
pubmed: 11725922
doi: 10.1081/JDI-100107372
pmcid: 11725922
Shimizu T, Iwamoto N, Okamoto M, Endo Y, Tsuji S, Takatani A et al (2019) Scleroderma renal crisis complicated with thrombotic microangiopathy triggered by influenza b virus infection. Intern Med 58(3):441–445
pubmed: 30146597
doi: 10.2169/internalmedicine.1441-18
pmcid: 30146597
Devresse A, Aydin S, Quintrec M, Demoulin N, Stordeur P, Lambert C, Gastoldi S, Pirson Y, Jadoul M, Morelle J (2016) Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore) 95(30):44–59
doi: 10.1097/MD.0000000000004459
Allinovi M, Cirami CL, Caroti L, Antognoli G, Farsetti S, Amato MP, Minetti EE (2017) Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. Clin Kidney J 10(5):625–631
pubmed: 28980667
doi: 10.1093/ckj/sfw143
pmcid: 28980667
Asif A, Nayer A, Haas CS (2017) Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 30(3):347–362
pubmed: 27848226
doi: 10.1007/s40620-016-0357-7
pmcid: 27848226